MiR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer

Brian D. Adams, Vikram B. Wali, Christopher J. Cheng, Sachi Inukai, Carmen J. Booth, Seema Agarwal, David L. Rimm, Balázs Györffy, Libero Santarpia, Lajos Pusztai, W. Mark Saltzman, Frank J. Slack

Research output: Contribution to journalArticlepeer-review


Triple-negative breast cancer (TNBC) is an aggressive subtype with no clinically proven biologically targeted treatment options. The molecular heterogeneity of TNBC and lack of high frequency drivermutations other than TP53 have hindered the development of new and effective therapies that significantly improve patient outcomes. miRNAs, global regulators of survival and proliferation pathways important in tumor development and maintenance, are becoming promising therapeutic agents. We performed miRNA-profiling studies in different TNBC subtypes to identify miRNAs that significantly contribute to disease progression. We found that miR-34a was lost in TNBC, specifically within mesenchymal and mesenchymal stem cell-like subtypes, whereas expression of miR-34a targets was significantly enriched. Furthermore, restoration of miR-34a in cell lines representing these subtypes inhibited proliferation and invasion, activated senescence, and promoted sensitivity to dasatinib by targeting the proto-oncogene c-SRC. Notably, SRC depletion in TNBC cell lines phenocopied the effects of miR- 34a reintroduction, whereas SRC overexpression rescued the antitumorigenic properties mediated by miR-34a. miR-34a levels also increased when cells were treated with c-SRC inhibitors, suggesting a negative feedback exists between miR-34a and c-SRC. Moreover, miR-34a administration significantly delayed tumor growth of subcutaneously and orthotopically implanted tumors in nude mice, and was accompanied by c- SRC downregulation. Finally, we found that miR-34a and SRC levels were inversely correlated in human tumor specimens. Together, our results demonstrate that miR-34a exerts potent antitumorigenic effects in vitro and in vivo and suggests that miR-34a replacement therapy, which is currently being tested in human clinical trials, represents a promising therapeutic strategy for TNBC.

Original languageEnglish
Pages (from-to)927-939
Number of pages13
JournalCancer Research
Issue number4
Publication statusPublished - Feb 15 2016

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'MiR-34a silences c-SRC to attenuate tumor growth in triple-negative breast cancer'. Together they form a unique fingerprint.

Cite this